뉴스벤징가
Aptevo Therapeutics Reports 93% Clinical Benefit Rate in Key Leukemia Trial
· 발표
기사 요약
Aptevo Therapeutics announced a 93% clinical benefit rate for mipletamig in frontline acute myeloid leukemia trial results.
기사 원문에서 발췌했어요.Aptevo Therapeutics announced a 93% clinical benefit rate for mipletamig in frontline acute myeloid leukemia trial results.
기사 원문에서 발췌했어요.
댓글 —
댓글을 불러오고 있어요…